Compare iShares MSCI China ETF (MCHI) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Smith & Nephew plc — how do they compare? iShares MSCI China ETF trades at $52.57 (market cap $5.94B), while Smith & Nephew plc trades at $27.31 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Smith & Nephew plc for 120 Days on average.
| MCHI | SNN | |
|---|---|---|
Market Cap | $5.94B | $11.10B |
Volume | 1,575,471 | 1,051,703 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $37.17 |
52-Week Low | $50.48 | $26.42 |
Typical Hold Time | 63 Days | 120 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI, the iShares MSCI China ETF, trades at $51.64, down 1.11% with a bearish technical outlook. The ETF faces pressure from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights mixed signals with strong corporate profit growth but concerns about export controls and trade tensions. Technical indicators show strong bearish momentum with moving averages signaling sell pressure while oscillators remain neutral.
The outlook remains cautious given China's macroeconomic headwinds and trade uncertainties. Investment opportunity exists in MCHI's significant discount to historical valuations compared to US indices, but risks include potential export restrictions, protectionism threats, and ongoing economic rebalancing challenges that could pressure Chinese equities.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
